$MCRB

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant ( AMR ) infections Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for ...

Original reporting
GlobeNewswire · Seres Therapeutics, Inc.
Published Oct 29, 2025, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 29, 2025, 11:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 — source image
Decision brief

The 30-second read

$MCRBNeutralLow
01

Why it matters

This development could positively influence Seres Therapeutics' stock in the long term but has limited immediate market impact.

02

Market read

The news is relevant to biotech investors and stakeholders interested in antimicrobial resistance solutions, but has limited immediate impact on broader markets.

03

What to watch

Potential delays in development or regulatory hurdles could mitigate positive impacts.

Timing: short-term

Background

Seres Therapeutics received a substantial award from CARB-X to develop a liquid formulation of SER-155, aiming to improve patient access and combat antimicrobial resistance.

Company-level read

Ticker impact

$MCRBNeutralMedium confidence
Context

Moderate relevance due to its presence in the news topics and neutral sentiment.

Expected impact

Minimal to no immediate price movement expected.

Evidence & confidence

The news focuses on Seres Therapeutics' funding, which does not directly involve MCRB, and its sentiment remains neutral.

Market effects

Potential positive sentiment in biotech and life sciences sectors due to increased funding and development activity.

Limited regional impact; primarily relevant to US biotech sector.

Minimal global market impact; news is sector-specific.

Counterpoint

The funding announcement may be overhyped and not translate into short-term stock movements.

Key entities

  • Seres Therapeutics

    Biotech company focusing on microbiome therapeutics.

  • CARB-X

    Public-private partnership supporting antimicrobial innovation.

Related articles

$MCRBMed

Seres Therapeutics, Inc. (MCRB): Results of Operations and Financial Condition

Seres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d124829dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS Recently announced 80% of SER-155 recipients achieved immunosuppres

$AAPLMed

Apple Tests Chinese Memory Chips As Supply Crunch Pushes PC Giants Toward CXMT

The Wall Street Journal reported Apple is testing memory chips from China’s CXMT across iPhones and MacBooks and has held early talks to supply components for some China-sold devices. Apple is seeking White House approval amid “unsustainable” pricing from SK Hynix, Samsung, Micron and SanDisk. US rules limit customization, but off-the-shelf purchases may be allowed.

$MDTMed

Jury Orders Medtronic to Pay $88 Million After Finding Surgeons Were Not Adequately Warned About a Hernia Mesh

A federal jury ordered Medtronic’s Covidien unit to pay $88 million to Larry and Tammy Patterson after finding surgeons were not adequately warned about risks of Covidien’s Symbotex hernia mesh. The Aug. 4 verdict followed a three-week trial in Massachusetts. Jurors awarded $77 million to Larry and $11 million for loss of consortium, with no punitive damages.

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.